Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 07, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its planned Phase 1 clinical...
read article.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jul 05, 2022 9:30am
Algernon is 8 Million USD short of money they stated they...
needed to run their longshot Phase 1 studies while Chronic Cough sits indefinitely on the back burner getting cold. Weeeee DMT for brain surgery!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 05, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 04, 2022 11:14am
New Press Release - Algernon Pharmaceuticals Announces Closing of Public Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the closing of its...
read article.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jul 03, 2022 8:26am
A Mere 4 Years Of Algernon To Stare Down Bankruptcy.
https://algernonpharma.com/
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jul 01, 2022 1:27am
When Will They Ever Learn???
Chronic Cough: 50 Patient Proof of Concept Study Completed in 10 Months in UK. https://www.businesswire.com/news/home/20220629005372/en/Axalbion-Announces-Positive-Findings-from-Phase-2-Clinical-Study
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 30, 2022 10:27am
Excerpt from a Florida Hospital story about Ifenprofil.
"But there is hope. Westchester is among a few hospitals around the world studying a new drug. Dr. Jose Suarez: So were doing a trial with Algernon, a medication called Ifenprodil, which has been
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 30, 2022 3:46am
@ ceo.ca
https://ceo.ca/agn?63ef3efc7944
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 29, 2022 5:11am
Final Punch Of The Day...
Greed, Stubbornness & Feeling A lack Of Being In Control. Those are likely 3 Top Reasons Why Management will Barrel Ahead with Long Drawn Out Plans For The future viability Of Algernon
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jun 29, 2022 4:58am
RE:The Only Clock I'm Punching Is Algernon's Right In The Face.
Follow up post: Ifenprodil for IPF and Chronic Cough has always been Algernon's strongest drug candidate since its purchase from Nash Pharmaceuticals back in 2018. It was considered to be 10
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 29, 2022 2:50am
The Only Clock I'm Punching Is Algernon's Right In The Face.
The Effect Of Conducting A Gold Standard Chronic Cough Study In The USA
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jun 28, 2022 11:01pm
RE:Bellus Health, Patented mechanism of action
Very shallow threads coming out of bear breath's mug shot. I hold shares dating back to 2016 - the beginning of Alpha. Been said that. I have historical due diligence. You have baseless rants that
...more
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Post by
TheBearInTheWoods
on Jun 28, 2022 10:40pm
Bellus Health, Patented mechanism of action
With a management team that has a record of selling to pharma. Don't listen to the bag holder here, he's just upset that he bought at .35 and now they are raising at .0375 lmao
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 28, 2022 4:26pm
Bellus Health. One Trick Pony. Chronic Cough.
1 Billion USD Market Cap @ The Close. Running Wild & Free!!!
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 28, 2022 1:44am
Wack format. I wasn't attempting a popup video. smh
Yeah Whalewatcher1. It raises more questions than answers. What's worse is no one on any message board has any solid info to share. That's even wacker! People are tuned out of the process
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Nanalysis Announces Third Quarter 2024 Conference Call
GameSquare to Report Q3 2024 Financial Results on November 14, 2024
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
Learn About a Mining Portfolio of More Than 250 Projects and Royalties Across North America